Cargando…

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial

INTRODUCTION: The API AutosomalDominant AD (ADAD) Colombia Trial is a placebo‐controlled clinical trial of crenezumab in 252 cognitively unimpaired 30 to 60‐year‐old Presenilin 1 (PSEN1) E280A kindred members, including mutation carriers randomized to active treatment or placebo and non‐carriers who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rios‐Romenets, Silvia, Lopera, Francisco, Sink, Kaycee M., Hu, Nan, Lian, Qinshu, Guthrie, Heather, Smith, Jillian, Cho, William, Mackey, Howard, Langbaum, Jessica B., Thomas, Ronald G., Giraldo‐Chica, Margarita, Tobon, Carlos, Acosta‐Baena, Natalia, Muñoz, Claudia, Ospina, Paula, Tirado, Victoria, Henao, Eliana, Bocanegra, Yamile, Chen, Kewei, Su, Yi, Goradia, Dhruman, Thiyyagura, Pradeep, VanGilder, Paul S., Luo, Ji, Ghisays, Valentina, Lee, Wendy, Malek‐Ahmadi, Michael H., Protas, Hillary D., Chen, Yinghua, Quiroz, Yakeel T., Reiman, Eric M., Tariot, Pierre N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Featured Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819133/ https://www.ncbi.nlm.nih.gov/pubmed/32418361 http://dx.doi.org/10.1002/alz.12109

Ejemplares similares

Individualized network analysis: A novel approach to investigate tau PET using graph theory in the Alzheimer’s disease continuum
por: Protas, Hillary, et al.
Publicado: (2023)

PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers
por: Ghisays, Valentina, et al.
Publicado: (2021)

Brain imaging biomarkers for the Alzheimer’s Prevention Initiative
por: Chen, Kewei, et al.
Publicado: (2012)

Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan
por: Rios-Romenets, Silvia, et al.
Publicado: (2018)

Brain imaging measurements of fibrillar amyloid‐β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele
por: Ghisays, Valentina, et al.
Publicado: (2020)

The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort
por: Tariot, Pierre N., et al.
Publicado: (2018)

Sex Differences in Cognitive Abilities Among Children With the Autosomal Dominant Alzheimer Disease Presenilin 1 E280A Variant From a Colombian Cohort
por: Fox-Fuller, Joshua T., et al.
Publicado: (2021)

Effect of apolipoprotein genotype and educational attainment on cognitive function in autosomal dominant Alzheimer’s disease
por: Langella, Stephanie, et al.
Publicado: (2023)

Resistance to autosomal dominant Alzheimer’s in an APOE3-Christchurch homozygote: a case report
por: Arboleda-Velasquez, Joseph F., et al.
Publicado: (2019)

The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease
por: Langbaum, Jessica B., et al.
Publicado: (2020)

Cognitive Stimulation for Apathy in Probable Early-Stage Alzheimer's
por: Buettner, Linda L., et al.
Publicado: (2011)

The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer’s disease
por: Vila-Castelar, Clara, et al.
Publicado: (2020)

Visualizing Alzheimer's disease progression in low dimensional manifolds
por: Seo, Kangwon, et al.
Publicado: (2019)

Trajectory of Unawareness of Memory Decline in Individuals With Autosomal Dominant Alzheimer Disease
por: Vannini, Patrizia, et al.
Publicado: (2020)

Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks
por: Guthrie, Heather, et al.
Publicado: (2020)

White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer’s disease that emerge prior to dementia
por: Schoemaker, Dorothee, et al.
Publicado: (2022)

Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer’s disease
por: Hanseeuw, Bernard J., et al.
Publicado: (2019)

Associations between subregional thalamic volume and brain pathology in autosomal dominant Alzheimer’s disease
por: Pardilla-Delgado, Enmanuelle, et al.
Publicado: (2021)

The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease
por: Lopez Lopez, Cristina, et al.
Publicado: (2019)

Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials
por: Langlois, Carolyn M., et al.
Publicado: (2019)

Dynamic Causal Modeling of Preclinical Autosomal-Dominant Alzheimer’s Disease
por: Penny, Will, et al.
Publicado: (2018)

Association between an Alzheimer’s Disease-Related Index and APOE ε4 Gene Dose
por: Schraml, Frank, et al.
Publicado: (2013)

Alzheimer's Disease Risk Assessment Using Large-Scale Machine Learning Methods
por: Casanova, Ramon, et al.
Publicado: (2013)

Spectral Analysis of EEG in Familial Alzheimer's Disease with E280A Presenilin-1 Mutation Gene
por: Rodriguez, Rene, et al.
Publicado: (2014)

Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease
por: Caputo, Angelika, et al.
Publicado: (2023)

Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer’s disease: findings from the Colombia-Boston (COLBOS) biomarker study
por: Sanchez, Justin S., et al.
Publicado: (2021)

Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man
por: Lopera, Francisco, et al.
Publicado: (2023)

Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations
por: Petersen, Ronald C., et al.
Publicado: (2023)

Plasma NfL is associated with the APOE ε4 allele, brain imaging measurements of neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-aged and older adults
por: Malek-Ahmadi, Michael, et al.
Publicado: (2023)

Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer’s disease
por: Norton, Daniel J., et al.
Publicado: (2020)

Present Algorithms and Future Treatments for Alzheimer’s Disease
por: Grossberg, George T., et al.
Publicado: (2019)

A Spanish Neuropsychological Battery Discriminates Between the Behavioral Variant of Frontotemporal Dementia and Primary Progressive Aphasia in a Colombian Sample
por: Velilla, Lina, et al.
Publicado: (2021)

Cerebral blood flow in Alzheimer’s disease
por: Roher, Alex E, et al.
Publicado: (2012)

Deep learning-based brain transcriptomic signatures associated with the neuropathological and clinical severity of Alzheimer’s disease
por: Wang, Qi, et al.
Publicado: (2021)

AD-NET: Age-adjust neural network for improved MCI to AD conversion prediction
por: Gao, Fei, et al.
Publicado: (2020)

Longitudinal changes in surface based brain morphometry measures in amnestic mild cognitive impairment and Alzheimer’s Disease
por: Bachmann, Tobias, et al.
Publicado: (2023)

Amyloid-beta immunotherapy: the hope for Alzheimer disease?
por: Barrera-Ocampo, Alvaro, et al.
Publicado: (2016)

Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer’s Prevention Trial: A global Perspective from the API Generation Program
por: Walsh, T., et al.
Publicado: (2023)

Cortical thickness across the lifespan in a Colombian cohort with autosomal‐dominant Alzheimer's disease: A cross‐sectional study
por: Fox‐Fuller, Joshua T., et al.
Publicado: (2021)

Amyloid-β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer’s disease
por: Guzmán-Vélez, Edmarie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_68pfe0dgm5p0a96sich34m0e9o